SAN DIEGO, April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ. NTLA) ....
LOS ANGELES--(BUSINESS WIRE)--NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm... .
NTLA) ... Among other items, Intellia announced that it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and will discontinue development of NTLA-3001, which will result in the Company cutting around 27% of its workforce ... .
Faruqi & Faruqi, LLP Securities Litigation PartnerJames (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options... .
Faruqi & Faruqi, LLP Securities Litigation PartnerJames (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options... .
NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
NTLA) of a class action securities lawsuit ... NTLA investors may also contact Joseph E ... study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease.